Board change at Ambrilia
This article was originally published in Scrip
Executive Summary
Ambrilia Biopharma, a Canadian biotechnology company discovering and developing treatments for viral diseases and cancer, has announced that Dr Philippe Calais, its former president & CEO, has resigned as a member of its board of directors. Dr Calais will serve as a consultant to the company for the next six months.